Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype

International Journal of Molecular Sciences

Renato Cannizzaro¹  Mara Fornasarig¹  Mariangela De Zorzi²  Agostino Steffan²  Laura Caggiari²  Valli De Re²  Giuseppe Palmieri³  Giovanni Lo Re⁴  Angela Buonadonna⁵  Gianmaria Miolo⁵  Debora Basile⁵  Fabio Puglisi⁵  Antonio Cossu⁶  Lara Alessandrini⁷  Vincenzo Canzonieri⁷  Davide A. Santeufemia⁸ 

[1] Gastroenterology, IRCCS CRO National Cancer Institute, 33081 Aviano, Italy;Immunopathology and Cancer Biomarkers, IRCCS CRO National Cancer Institute, 33081 Aviano, Italy;Institute of Biomolecular Chemistry, Cancer Genetics Unit, C.N.R., 07100 Sassari, Italy;Medical Oncology Department, Santa Maria degli Angeli Hospital, 33170 Pordenone, Italy;Medical Oncology, IRCCS, CRO National Cancer Institute, 33081 Aviano, Italy;Operative Unit of Pathology Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, 07100 Sassari, Italy;Pathology, IRCCS CRO National Cancer Institute, 33081 Aviano, Italy;SSD Oncology, Ospedale Civile Alghero, 07041 Alghero, Italy;

关键词: E-cadherin;    CDH1;    HER2;    metastatic gastric cancer;    rs16260;    rs1801552;   

DOI  :  10.3390/ijms19010047

来源: DOAJ

【 摘 要 】

The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC. HER2 is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a fraction of patients. The aim of this study was to improve knowledge of the HER2 and the E-cadherin alterations in the context of GC to characterize subtypes of patients that could better benefit from targeted therapy. An association between the P7-CDH1 haplotype, including two polymorphisms (rs16260A-rs1801552T) and a subset of HER2-positive mGC with better prognosis was observed. Results indicated the potential evaluation of CDH1 haplotypes in mGC to stratify patients that will benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding the HER2 and the E-cadherin interactions in vivo and in response to treatments.

【 授权许可】

Unknown